Organigram Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>OH</div>
OGI -- USA Stock  

USD 1.74  0.02  1.16%

As many millenniums are trying to avoid healthcare space, it makes sense to concentrate on Organigram Hlds a little further and try to understand its current market patterns. As expected, Organigram Hlds is starting to reaffirm its true potential as stockholders are becoming more and more confident in the future outlook. The company returns are related to returns on the market. As market wavers, the company is expected to follow. Fragile basic indicators of the company may also hint to signs of long-run losses for Organigram stockholders. Organigram Hlds is scheduled to announce its earnings tomorrow. The next earnings report is expected on the 12th of January 2021. The stock goes through above-average trading activities.
Published over a month ago
View all stories for Organigram Hlds | View All Stories
Is Organigram (NASDAQ:OGI) outlook still optimistic?
Organigram Hlds's average rating is Hold from 12 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Organigram Hlds market sentiment investors' perception of the future value of Organigram. Let us look at a few aspects of Organigram technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Organigram Hlds. In general, we focus on analyzing Organigram Hlds stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Organigram Hlds's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Organigram Hlds's intrinsic value. In addition to deriving basic predictive indicators for Organigram Hlds, we also check how macroeconomic factors affect Organigram Hlds price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Organigram Hlds' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Organigram Hlds in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Organigram Hlds. Your research has to be compared to or analyzed against Organigram Hlds' peers to derive any actionable benefits. When done correctly, Organigram Hlds' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Organigram Hlds.

How does Organigram Stands against Peers?

Analyzing Organigram Hlds competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Organigram Hlds across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Organigram Hlds Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Organigram Hlds, but it might be worth checking our own buy vs. sell analysis

Closer look at Organigram Hlds Semi Deviation

Organigram Hlds has current Semi Deviation of 4.73. Semi-deviation provides a good measure of downside risk for a equity or a portfolio. It is similar to standard deviation, but it only looks at periods where the returns are less than the target or average level.

Semi-deviation is the square root of semi-variance. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Deviation 
=  
SQRT(SV) 
 = 
4.73
SQRT = Square root notation
SV =   Organigram Hlds semi variance of returns over selected period
Let's now compare Organigram Hlds Semi Deviation to its closest peers:
OGI
BHC
ELAN
ENDP
ACB
OGI4.734223721863008
BHC2.38
ELAN2.25
ENDP3.24
ACB7.39

Our take on today Organigram Hlds rise

The downside variance is down to 31.23 as of today. Organigram Hlds exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Organigram Hlds individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Organigram Hlds future systematic risk.

Our Final Take On Organigram Hlds

While other companies within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Organigram Hlds may offer a potential longer-term growth to stockholders. To conclude, as of the 29th of November 2020, our final 30 days buy-or-sell advice on the company is Strong Sell. However, we believe Organigram Hlds is undervalued with below average probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Organigram Hlds. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com